Antibiotic Treatment for Gastrointestinal Infections

Community-Acquired GI Infections

For mild to moderate community-acquired gastrointestinal infections, first-line treatments include amoxicillin-clavulanic acid or cefotaxime/ceftriaxone with metronidazole, while ciprofloxacin with metronidazole is recommended as second-line therapy, according to the Infectious Diseases Society of America 1
Cefotaxime or ceftriaxone + metronidazole is recommended as first-line therapy for severe community-acquired infections, with a strength of evidence based on clinical guidelines 1
Ertapenem, moxifloxacin, or tigecycline as single agents are recommended as second-line options for community-acquired GI infections, with a moderate strength of evidence 2, 3
Ampicillin-sulbactam is not recommended due to high rates of resistance among E. coli, with a high strength of evidence based on resistance patterns 3
Aminoglycosides are not recommended for routine use due to toxicity concerns, with a high strength of evidence based on clinical studies 3, 4

For pediatric patients, acceptable regimens include aminoglycoside-based regimens, carbapenems, β-lactam/β-lactamase inhibitor combinations, and advanced-generation cephalosporins with metronidazole, with a moderate strength of evidence based on clinical guidelines 5, 6

Antimicrobial therapy should be continued until resolution of clinical signs of infection, including normalization of temperature, WBC count, and return of gastrointestinal function, with a high strength of evidence based on clinical studies 4
Blood cultures are not routinely recommended for community-acquired infections, but may be considered if the patient appears clinically toxic or is immunocompromised, with a moderate strength of evidence based on clinical guidelines 2

Quinolone-resistant E. coli has become common in some communities, and quinolones should not be used unless hospital surveys indicate >90% susceptibility, with a high strength of evidence based on resistance patterns 7
Increasing resistance among B. fragilis isolates is concerning and associated with higher failure rates, with a moderate strength of evidence based on clinical studies 3
Local microbiologic findings should be reviewed, as broader-spectrum regimens may be required in areas with high resistance, with a moderate strength of evidence based on clinical guidelines 7